皮膚がんの皮膚科市場：検査別、年齢層別、施設タイプ別-2025-2030年の世界予測

皮膚がんの皮膚科市場は、2023年に77億8,000万米ドルと評価され、2024年には84億2,000万米ドルに達すると予測され、CAGR 7.40％で成長し、2030年には128億3,000万米ドルに達すると予測されています。

皮膚がんの皮膚科市場の範囲は、外科的、局所的、全身的治療を含む予防、診断、治療技術を包含します。高齢化、紫外線暴露の増加、オゾン層の破壊などを背景に、世界的に皮膚がんの罹患率が上昇しているため、この市場は不可欠です。市場の用途は、製薬、バイオテクノロジー、病院、皮膚科クリニック、研究機関など多岐にわたる。最終用途の範囲は、患者の診断からオーダーメイドの治療介入にまで及ぶ。主な成長促進要因としては、診断におけるAIのような技術的進歩、ヘルスケアに対する意識の向上、早期発見のための政府の支援策が挙げられます。さらに、革新的な局所療法や免疫療法の商業化は、特に個別化医療領域において潜在的な機会をもたらします。こうした機会を捉えるために、企業はデジタル皮膚健康モニタリングツールやAI主導の診断プラットフォームに投資すべきです。しかし、高額な治療費、規制上のハードル、保険償還の複雑さなどの制約が市場成長の課題となっています。発展途上地域では、認知度の低さと限られたヘルスケアインフラがさらなる障壁となっています。革新的な成長分野としては、光干渉断層計などの非侵襲的診断技術や新規光保護剤の開発が挙げられます。また、標的治療のための遺伝学的・分子生物学的研究開発も市場開拓を促進する可能性があります。遠隔皮膚科学や在宅皮膚がん検診ツールに関する洞察は、遠隔地での個別化された患者ケアへの市場のシフトを浮き彫りにしています。市場の競争は激しく、主要企業はポートフォリオを強化するためにM&Aを積極的に行っています。R&D投資の増加とヘルスケアのデジタル変革により、市場は力強い成長の可能性を秘めているが、企業はこの情勢をうまく乗り切り、課題的であると同時にダイナミックな市場で有利なポジションを確立するために、現在の制限に対処し、規制状況に注力する必要があります。

市場力学：急速に進化する皮膚がんの皮膚科市場の主要市場インサイトを公開

皮膚がんの皮膚科市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の皮膚がんの増加
  • 高度なヘルスケアインフラの利用可能性
  • 皮膚がんに対する意識の高まり
• 市場抑制要因
  • 治療費の高騰
• 市場機会
  • テレダーマトロジーの導入による継続的な発展
  • スマートフォン対応診断機器の増加
• 市場の課題
  • 承認と治療に関する厳しい規制の枠組み

ポーターのファイブフォース：皮膚がんの皮膚科市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：皮膚がんの皮膚科市場における外部からの影響の把握

外部マクロ環境要因は、皮膚がんの皮膚科市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：皮膚がんの皮膚科市場における競合情勢の把握

皮膚がんの皮膚科市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス：皮膚がんの皮膚科市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、皮膚がんの皮膚科市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：皮膚がんの皮膚科市場における成功への道筋を描く

皮膚がんの皮膚科市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で皮膚がんの発生率が増加
    • 高度なヘルスケアインフラの可用性
    • 国民の間で皮膚がんに対する意識が高まる
  • 抑制要因
    • 資本集約的な治療とセラピー
  • 機会
    • 遠隔皮膚科のイントロダクションよる継続的な発展
    • スマートフォン対応診断機器の増加
  • 課題
    • 承認と治療に関する厳格な規制枠組み
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 皮膚がんの皮膚科市場テスト別

• 皮膚鏡検査
• 診断画像
• リンパ節生検
• 皮膚生検

第7章 皮膚がんの皮膚科市場：年齢層別

• 0-19
• 20-39
• 40-59
• 60-64
• 65-74
• 75-84
• 85歳以上

第8章 皮膚がんの皮膚科市場施設タイプ別

• 皮膚科グループ
• 病院外来
• 多科クリニック
• 独立した実践

第9章 南北アメリカの皮膚がんの皮膚科市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の皮膚がんの皮膚科市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの皮膚がんの皮膚科市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Amgen, Inc.
• Bristol-Myers Squibb Company
• Canfield Scientific, Inc.
• Colleyville Dermatology
• Cutera, Inc.
• FotoFinder Systems, Inc.
• Merck & Co., Inc.
• MetaOptima Technology Inc.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals, Inc.
• Sanofi S.A.
• Skin Analytics Pty Ltd.
• Speclipse, Inc.
• Sun Pharmaceutical Industries Limited

LIST OF FIGURES

• FIGURE 1. SKIN CANCER DERMATOLOGY MARKET RESEARCH PROCESS
• FIGURE 2. SKIN CANCER DERMATOLOGY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL SKIN CANCER DERMATOLOGY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL SKIN CANCER DERMATOLOGY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL SKIN CANCER DERMATOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS SKIN CANCER DERMATOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS SKIN CANCER DERMATOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES SKIN CANCER DERMATOLOGY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES SKIN CANCER DERMATOLOGY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC SKIN CANCER DERMATOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC SKIN CANCER DERMATOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DERMATOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DERMATOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. SKIN CANCER DERMATOLOGY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. SKIN CANCER DERMATOLOGY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. SKIN CANCER DERMATOLOGY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL SKIN CANCER DERMATOLOGY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL SKIN CANCER DERMATOLOGY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL SKIN CANCER DERMATOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. SKIN CANCER DERMATOLOGY MARKET DYNAMICS
• TABLE 7. GLOBAL SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL SKIN CANCER DERMATOLOGY MARKET SIZE, BY DERMATOSCOPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL SKIN CANCER DERMATOLOGY MARKET SIZE, BY DIAGNOSTIC IMAGING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL SKIN CANCER DERMATOLOGY MARKET SIZE, BY LYMPH NODE BIOPSY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL SKIN CANCER DERMATOLOGY MARKET SIZE, BY SKIN BIOPSY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL SKIN CANCER DERMATOLOGY MARKET SIZE, BY 0-19, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL SKIN CANCER DERMATOLOGY MARKET SIZE, BY 20-39, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL SKIN CANCER DERMATOLOGY MARKET SIZE, BY 40-59, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL SKIN CANCER DERMATOLOGY MARKET SIZE, BY 60-64, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL SKIN CANCER DERMATOLOGY MARKET SIZE, BY 65-74, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL SKIN CANCER DERMATOLOGY MARKET SIZE, BY 75-84, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL SKIN CANCER DERMATOLOGY MARKET SIZE, BY 85 & ABOVE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL SKIN CANCER DERMATOLOGY MARKET SIZE, BY DERMATOLOGY GROUP, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL SKIN CANCER DERMATOLOGY MARKET SIZE, BY HOSPITAL OPD, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL SKIN CANCER DERMATOLOGY MARKET SIZE, BY MULTISPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL SKIN CANCER DERMATOLOGY MARKET SIZE, BY STAND ALONE PRACTICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS SKIN CANCER DERMATOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 35. CANADA SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 36. CANADA SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 37. CANADA SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 38. MEXICO SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 41. UNITED STATES SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 42. UNITED STATES SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES SKIN CANCER DERMATOLOGY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 45. ASIA-PACIFIC SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 46. ASIA-PACIFIC SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 47. ASIA-PACIFIC SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC SKIN CANCER DERMATOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 49. AUSTRALIA SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 50. AUSTRALIA SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 51. AUSTRALIA SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. CHINA SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 53. CHINA SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 54. CHINA SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. INDIA SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 56. INDIA SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 57. INDIA SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. INDONESIA SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 59. INDONESIA SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 60. INDONESIA SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. JAPAN SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 62. JAPAN SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 63. JAPAN SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. MALAYSIA SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 65. MALAYSIA SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 66. MALAYSIA SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. PHILIPPINES SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 68. PHILIPPINES SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 69. PHILIPPINES SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. SINGAPORE SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 71. SINGAPORE SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 72. SINGAPORE SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. SOUTH KOREA SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 74. SOUTH KOREA SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 75. SOUTH KOREA SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. TAIWAN SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 77. TAIWAN SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 78. TAIWAN SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 79. THAILAND SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 80. THAILAND SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 81. THAILAND SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. VIETNAM SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 83. VIETNAM SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 84. VIETNAM SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 85. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 86. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 87. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 88. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DERMATOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 89. DENMARK SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 90. DENMARK SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 91. DENMARK SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. EGYPT SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 93. EGYPT SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 94. EGYPT SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. FINLAND SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 96. FINLAND SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 97. FINLAND SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. FRANCE SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 99. FRANCE SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 100. FRANCE SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 101. GERMANY SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 102. GERMANY SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 103. GERMANY SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. ISRAEL SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 105. ISRAEL SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 106. ISRAEL SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. ITALY SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 108. ITALY SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 109. ITALY SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. NETHERLANDS SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 111. NETHERLANDS SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 112. NETHERLANDS SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. NIGERIA SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 114. NIGERIA SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 115. NIGERIA SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. NORWAY SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 117. NORWAY SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 118. NORWAY SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. POLAND SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 120. POLAND SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 121. POLAND SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. QATAR SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 123. QATAR SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 124. QATAR SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. RUSSIA SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 126. RUSSIA SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 127. RUSSIA SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SAUDI ARABIA SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 129. SAUDI ARABIA SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 130. SAUDI ARABIA SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH AFRICA SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 132. SOUTH AFRICA SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 133. SOUTH AFRICA SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 134. SPAIN SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 135. SPAIN SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 136. SPAIN SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. SWEDEN SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 138. SWEDEN SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 139. SWEDEN SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. SWITZERLAND SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 141. SWITZERLAND SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 142. SWITZERLAND SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. TURKEY SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 144. TURKEY SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 145. TURKEY SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 146. UNITED ARAB EMIRATES SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 147. UNITED ARAB EMIRATES SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 148. UNITED ARAB EMIRATES SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 149. UNITED KINGDOM SKIN CANCER DERMATOLOGY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 150. UNITED KINGDOM SKIN CANCER DERMATOLOGY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 151. UNITED KINGDOM SKIN CANCER DERMATOLOGY MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 152. SKIN CANCER DERMATOLOGY MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 153. SKIN CANCER DERMATOLOGY MARKET, FPNV POSITIONING MATRIX, 2023

The Skin Cancer Dermatology Market was valued at USD 7.78 billion in 2023, expected to reach USD 8.42 billion in 2024, and is projected to grow at a CAGR of 7.40%, to USD 12.83 billion by 2030.

The scope of the skin cancer dermatology market encompasses prevention, diagnosis, and treatment technologies, including surgical, topical, and systemic therapies. It is essential due to the rising incidence of skin cancer globally, driven by aging populations, increased UV exposure, and ozone layer depletion. The market applications range across pharmaceutical and biotechnological sectors, hospitals, dermatology clinics, and research institutions. End-use scope extends from patient diagnostics to tailored therapeutic interventions. Key growth drivers include technological advancements like AI in diagnostics, increased healthcare awareness, and supportive government initiatives for early detection. Furthermore, the commercialization of innovative topical therapies and immunotherapies presents potential opportunities, particularly in the personalized medicine domain. To seize these opportunities, companies should invest in digital skin health monitoring tools and AI-driven diagnostic platforms. However, limitations such as high treatment costs, regulatory hurdles, and the complexity of insurance reimbursements challenge market growth. In developing regions, the lack of awareness and limited healthcare infrastructure pose additional barriers. Innovative areas for growth include non-invasive diagnostic technologies, such as optical coherence tomography, and the development of novel photoprotective agents. Exploring genetic and molecular research for targeted therapies could also propel market developments. Insights into teledermatology and home-based skin cancer screening tools highlight the market's shift towards remote and personalized patient care. The nature of the market is highly competitive, with key players actively engaging in mergers and acquisitions to enhance their portfolios. While the market offers robust growth potential due to increased R&D investments and healthcare's digital transformation, companies must address current limitations and focus on regulatory compliance to successfully navigate this landscape and position themselves advantageously in a market that is as dynamic as it is challenging.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Skin Cancer Dermatology Market

The Skin Cancer Dermatology Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing incidences of skin cancer worldwide
  • Availability of advanced healthcare infrastructure
  • Rising awareness about skin cancer among the population
• Market Restraints
  • Capital intensive treatment with therapy
• Market Opportunities
  • Ongoing development with introduction of teledermatology
  • Increasing number of smartphone-compatible diagnostic devices
• Market Challenges
  • Strict regulatory framework for the approval and treatment

Porter's Five Forces: A Strategic Tool for Navigating the Skin Cancer Dermatology Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Skin Cancer Dermatology Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Skin Cancer Dermatology Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Skin Cancer Dermatology Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Skin Cancer Dermatology Market

A detailed market share analysis in the Skin Cancer Dermatology Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Skin Cancer Dermatology Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Skin Cancer Dermatology Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Skin Cancer Dermatology Market

A strategic analysis of the Skin Cancer Dermatology Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Skin Cancer Dermatology Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amgen, Inc., Bristol-Myers Squibb Company, Canfield Scientific, Inc., Colleyville Dermatology, Cutera, Inc., FotoFinder Systems, Inc., Merck & Co., Inc., MetaOptima Technology Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A., Skin Analytics Pty Ltd., Speclipse, Inc., and Sun Pharmaceutical Industries Limited.

Market Segmentation & Coverage

This research report categorizes the Skin Cancer Dermatology Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Test, market is studied across Dermatoscopy, Diagnostic Imaging, Lymph Node Biopsy, and Skin Biopsy.
• Based on Age Group, market is studied across 0-19, 20-39, 40-59, 60-64, 65-74, 75-84, and 85 & Above.
• Based on Facility Type, market is studied across Dermatology Group, Hospital OPD, Multispecialty Clinics, and Stand Alone Practices.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing incidences of skin cancer worldwide
    • 5.1.1.2. Availability of advanced healthcare infrastructure
    • 5.1.1.3. Rising awareness about skin cancer among the population
  • 5.1.2. Restraints
    • 5.1.2.1. Capital intensive treatment with therapy
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing development with introduction of teledermatology
    • 5.1.3.2. Increasing number of smartphone-compatible diagnostic devices
  • 5.1.4. Challenges
    • 5.1.4.1. Strict regulatory framework for the approval and treatment
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Skin Cancer Dermatology Market, by Test

• 6.1. Introduction
• 6.2. Dermatoscopy
• 6.3. Diagnostic Imaging
• 6.4. Lymph Node Biopsy
• 6.5. Skin Biopsy

7. Skin Cancer Dermatology Market, by Age Group

• 7.1. Introduction
• 7.2. 0-19
• 7.3. 20-39
• 7.4. 40-59
• 7.5. 60-64
• 7.6. 65-74
• 7.7. 75-84
• 7.8. 85 & Above

8. Skin Cancer Dermatology Market, by Facility Type

• 8.1. Introduction
• 8.2. Dermatology Group
• 8.3. Hospital OPD
• 8.4. Multispecialty Clinics
• 8.5. Stand Alone Practices

9. Americas Skin Cancer Dermatology Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Skin Cancer Dermatology Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Skin Cancer Dermatology Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Amgen, Inc.
• 3. Bristol-Myers Squibb Company
• 4. Canfield Scientific, Inc.
• 5. Colleyville Dermatology
• 6. Cutera, Inc.
• 7. FotoFinder Systems, Inc.
• 8. Merck & Co., Inc.
• 9. MetaOptima Technology Inc.
• 10. Novartis AG
• 11. Pfizer Inc.
• 12. Regeneron Pharmaceuticals, Inc.
• 13. Sanofi S.A.
• 14. Skin Analytics Pty Ltd.
• 15. Speclipse, Inc.
• 16. Sun Pharmaceutical Industries Limited